A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Blood. 2017.
PMID: 28336527
Free PMC article.
Clinical Trial.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2026 | 0 |
Search Results
4 results
Results by year
Citations
2
articles
found by citation matching
Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.
Blood. 2020.
PMID: 32645169
Free PMC article.
No abstract available.
Search results
Page 1
Did you mean
a phase a clinical trial of single agent selinefor in acute myeloid leukemia.
(292 results)?
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.
Blood. 2017.
PMID: 28336527
Free PMC article.
Clinical Trial.
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study was initiated to examin …
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads …
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Clin Cancer Res. 2020 Jan 1;26(1):54-60. doi: 10.1158/1078-0432.CCR-19-2169. Epub 2019 Oct 21.
Clin Cancer Res. 2020.
PMID: 31636097
Free PMC article.
Clinical Trial.
PURPOSE: Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. ...PATIENTS AND METHODS: This was a sing …
PURPOSE: Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor i …
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Leuk Lymphoma. 2023 Dec;64(13):2091-2100. doi: 10.1080/10428194.2023.2253480. Epub 2023 Sep 4.
Leuk Lymphoma. 2023.
PMID: 37665178
Clinical Trial.
Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clinical trials of relapsed/refractory (R/R) acute myeloid leukemia (AML) and preclinical synergy with topoisomerase (topo) …
Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clin …
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
J Hematol Oncol. 2018 Jan 5;11(1):4. doi: 10.1186/s13045-017-0550-8.
J Hematol Oncol. 2018.
PMID: 29304833
Free PMC article.
Clinical Trial.
BACKGROUND: Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single …
BACKGROUND: Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with …
Cite